The conversation is about a person starting treatment with RU58841 for hair loss. They are asked to share progress pictures to show if the treatment is effective.
The conversation is about finding a trustworthy and affordable source for RU58841 in Europe, with a comparison between Anagenic and Actifolic. The user seeks experiences from others in the EU to avoid receiving water instead of the product.
The user has not seen results from various hair loss treatments including finasteride, dutasteride, minoxidil, and others over several years and is considering adding RU58841 and starting hormone replacement therapy. They are also experiencing anxiety and contemplating moving to a more accepting environment for their nonbinary identity.
Fluridil may decrease the number of androgen receptors in hair follicles by up to 95%. This suggests a different action mechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.
Clascoterone and RU58841 are compared for effectiveness in treating hair loss. The discussion involves treatments like Minoxidil, finasteride, and RU58841.
A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
The conversation discusses recommendations for using topical melatonin for hair loss treatment. It also mentions Minoxidil, finasteride, and RU58841 as other treatments.
RU58841 has significantly improved the user's hair loss experience, alongside oral finasteride, dutasteride, 5 mg minoxidil, topical finasteride, dermastamping, and low-level laser therapy. The user is considering increasing their RU58841 dose from 75 mg to 100-150 mg daily.
The conversation is about hair loss treatments, including dermarolling, Minoxidil, Finasteride, and RU58841. Users discuss their experiences, side effects, and application methods for these treatments.
A user suggests making a potent sulforaphane topical to degrade DHT and promote hair growth. Another user notes that sulforaphane's low molecular weight might also lower systemic DHT.
The user is addressing hair loss with finasteride, dutasteride, oral and topical minoxidil, dermarolling, and shampoos. They are considering adding essential oils to improve circulation.
User discusses Alfatradiol (17a-Estradiol) as a potential hair loss treatment with mixed results. Concerns include low dosage, receptor theory, and possible increased aromatase activity on scalp.
The relative strength of Pyrilutamide compared to RU58841 in terms of androgen receptor binding affinity. It has been noted that Pyrilutamide is 4x stronger than RU58841, with a higher binding affinity than DHT itself.
Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.
The user switched from finasteride to dutasteride for hair loss and saw significant improvement in under two months. They also microneedle, take supplements including collagen and vitamin D3, use ketoconazole shampoo, and noticed accidental hair regrowth with retinol application on their face.
Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.
The user reintroduced RU58841 and noticed increased shedding and visible thinning. They have also been using dutasteride and oral minoxidil for 2 years.
Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.
PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.
The conversation discusses hair regrowth using 2-deoxy-d-ribose (2DDR) combined with minoxidil, with some users noting new hair growth. The original poster has been using minoxidil for 12 years and is considering combining 2DDR with finasteride, despite past side effects.
The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.
OP believes RU58841 affected their thyroid, causing hypothyroidism and impacting minoxidil's effectiveness. They plan to start thyroid medication to improve hair regrowth.
A 26-year-old individual treating hair loss since 19, using a regimen of Finasteride, Cyproterone, Oral Minoxidil, Microneedling, Dutasteride, and newly added RU58841. They're seeking advice from other RU58841 users about their experiences.
The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.
A user shared their positive experience with the Omnilux Red Light mask for skin and potential hair benefits, while also using Minoxidil, Dutasteride, and RU58841. They recommend the mask for those interested in skincare and red light therapy, despite being unsure of its effectiveness for hair growth.
The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.